Characterizing the Network of Drugs and Their Affected Metabolic Subpathways
Figure 4
The relationship between drug dual effects and metabolic subpathways in the DRSN.
(A) Of 1586 connected drug pairs (drugs that were linked to the same subpathways), 67 shared the same indications, compared to 55 drug pairs on average of 1000 randomized 1586 drug pairs. Of 1000 times randomized 1586 drug pairs, there were only 36 times when the number of drug pairs which shared the same indications were more than 67 (P-value = 0.036). (B) The number of side effects shared by connected drug pairs was significantly higher than the number of side effects shared by all drug pairs in the SIDER database (P-value <10). (C) The number of shared side effects significantly increased as the number of the shared subpathways increased between two drugs (P-value = 0.0034). The grey horizontal line is the average number of side-effects all drug pairs shared. The Y axis represents the number of side-effects shared by drug pairs. The X axis represents the number of the same subpathways drug pairs shared. Blue “▪” symbols correspond to the binned average number of side-effects shared by drug pairs. The linear regression model (black line) is used to test the trends in correlations and the significance of the trends is estimated.